SANA
What one share of Sana Biotechnology holds
Biological Products, (No Diagnostic Substances)
We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant.
Sana Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.76 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.49 |
| Cash and investments | $0.54 |
| Book value | $0.52 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$26.67 | $5.33 | −$22.77 | — | −$29.07 |
| 2020 | — | −$21.92 | $1.83 | −$12.44 | — | −$26.05 |
| 2021 | — | −$2.14 | $0.18 | −$1.69 | — | $3.94 |
| 2022 | — | −$1.43 | $0.11 | −$1.65 | — | $2.61 |
| 2023 | — | −$1.46 | $0.10 | −$1.41 | — | $1.45 |
| 2024 | — | −$1.16 | $0.14 | −$1.11 | — | $1.12 |
| 2025 | — | −$0.96 | $0.00 | −$0.57 | — | $0.60 |